Northern Trust’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-46,072
| Closed | -$58.7K | – | 4623 |
|
|
2023
Q3 | $58.7K | Sell |
46,072
-69,138
| -60% | -$60.4K | ﹤0.01% | 4131 |
|
|
2023
Q2 | $37.6K | Hold |
115,210
| – | – | ﹤0.01% | 4284 |
|
|
2023
Q1 | $49.5K | Sell |
115,210
-1,547
| -1% | -$815 | ﹤0.01% | 4272 |
|
|
2022
Q4 | $61.9K | Hold |
116,757
| – | – | ﹤0.01% | 4228 |
|
|
2022
Q3 | $85K | Buy |
116,757
+1,775
| +2% | +$2.01K | ﹤0.01% | 4164 |
|
|
2022
Q2 | $131K | Sell |
114,982
-227
| -0.2% | -$289 | ﹤0.01% | 4069 |
|
|
2022
Q1 | $236K | Sell |
115,209
-5,260
| -4% | -$12.5K | ﹤0.01% | 4062 |
|
|
2021
Q4 | $347K | Sell |
120,469
-17,235
| -13% | -$63.8K | ﹤0.01% | 3950 |
|
|
2021
Q3 | $584K | Buy |
137,704
+16,960
| +14% | +$75.7K | ﹤0.01% | 3712 |
|
|
2021
Q2 | $639K | Buy |
120,744
+21,060
| +21% | +$101K | ﹤0.01% | 3637 |
|
|
2021
Q1 | $463K | Sell |
99,684
-25,052
| -20% | -$114K | ﹤0.01% | 3836 |
|
|
2020
Q4 | $412K | Sell |
124,736
-14,123
| -10% | -$53.6K | ﹤0.01% | 3771 |
|
|
2020
Q3 | $460K | Buy |
138,859
+4,885
| +4% | +$17.9K | ﹤0.01% | 3638 |
|
|
2020
Q2 | $451K | Sell |
133,974
-195,407
| -59% | -$924K | ﹤0.01% | 3579 |
|
|
2020
Q1 | $1.26M | Buy |
329,381
+13,307
| +4% | +$61.8K | ﹤0.01% | 3105 |
|
|
2019
Q4 | $1.91M | Buy |
316,074
+999
| +0.3% | +$6.83K | ﹤0.01% | 3151 |
|
|
2019
Q3 | $2.38M | Buy |
315,075
+215,577
| +217% | +$2.43M | ﹤0.01% | 3005 |
|
|
2019
Q2 | $1.35M | Buy |
99,498
+26,502
| +36% | +$306K | ﹤0.01% | 3254 |
|
|
2019
Q1 | $395K | Sell |
72,996
-13,959
| -16% | -$67.9K | ﹤0.01% | 3597 |
|
|
2018
Q4 | $258K | Sell |
86,955
-8,247
| -9% | -$45.2K | ﹤0.01% | 3725 |
|
|
2018
Q3 | $776K | Buy |
95,202
+32,461
| +52% | +$249K | ﹤0.01% | 3536 |
|
|
2018
Q2 | $612K | Sell |
62,741
-104,601
| -63% | -$1.07M | ﹤0.01% | 3556 |
|
|
2018
Q1 | $1.46M | Buy |
167,342
+24,663
| +17% | +$266K | ﹤0.01% | 3261 |
|
|
2017
Q4 | $1.79M | Buy |
142,679
+6,787
| +5% | +$77.8K | ﹤0.01% | 3199 |
|
|
2017
Q3 | $1.14M | Buy |
135,892
+16
| +0% | +$169 | ﹤0.01% | 3405 |
|
|
2017
Q2 | $2.31M | Buy |
135,876
+109,770
| +420% | +$2.18M | ﹤0.01% | 3094 |
|
|
2017
Q1 | $525K | Buy |
26,106
+1,859
| +8% | +$36.9K | ﹤0.01% | 3519 |
|
|
2016
Q4 | $378K | Buy |
24,247
+1,468
| +6% | +$19.8K | ﹤0.01% | 3595 |
|
|
2016
Q3 | $297K | Buy |
+22,779
| New | +$216K | ﹤0.01% | 3627 |
|
|
2016
Q2 | – | Sell |
-33,919
| Closed | -$321K | – | 4287 |
|
|
2016
Q1 | $321K | Hold |
33,919
| – | – | ﹤0.01% | 3575 |
|
|
2015
Q4 | $342K | Buy |
+33,919
| New | +$449K | ﹤0.01% | 3595 |
|
Northern Trust's ZYNE Position: Q4 2023 in Review
Northern Trust sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 46,072 shares — an estimated $58.7K sold.
Northern Trust first reported a position in ZYNE in Q4 2015 and held it in 31 quarters. The position peaked at $2.38M in Q3 2019. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- Northern Trust reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- Northern Trust sold 46,072 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $58.7K.
- Northern Trust first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2015 and held it in 31 quarters.
- Northern Trust's Zynerba Pharmaceuticals, Inc position peaked at $2.38M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on Northern Trust's 13F filing for Q4 2023, filed 13 Feb 2024.